Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intravenous infusion: once every week/every two weeks/every three weeks, each treatment cycle is 3 weeks/4 weeks/6 weeks.”In the company’s words, NCT07222969 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumors
- Main trialPhase 1/2
- “This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard treatments. This study is divided into a dose-escalation phase (Phase I) and a dose-expansion phase (Phase II). Phase I (dose escalation) is designed to preliminarily evaluate the safety and tolerability, PK profile, preliminary antitumor activity and immunogenicity of VIB305 in advanced solid tumors, to determine the nature and incidence of dose-limiting toxicities…”In the company’s words, NCT07222969 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 30 Sep 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovCompletion date moved: 2027-04-30 to 2027-09-30 · ClinicalTrials.gov NCT07222969
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Sep 2027 | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026